We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 49

AstraZeneca v. Apotex; interlocutory motion for reply evidence; esomeprazole

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • February 12 2010

The Court dismissed AstraZeneca's appeal from the order of a prothonotary refusing to strike parts of Apotex' evidence and refusing to permit the applicants to file reply

Apotex v. Pfizer

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • March 4 2009

The Court of Appeal dismissed the generic company's appeal and upheld the decision of the trial judge prohibiting Apotex entering the market until the expiry of the patent

Bristol-Myers Squibb v. Apotex

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 7 2009

The Court refused to grant prohibition on the basis that Apotex's allegation in respect of invalidity for obviousness was justified

Canada v. Pharmascience

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • July 27 2009

The Court of Appeal upheld the decision of the trial judge holding that the generic company was not required to address the patents listed on the patent register against submissions filed after it had purchased its comparator drug

Janssen-Ortho v. Apotex; interlocutory motion for reply evidence; methylphenidate

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • February 12 2010

In two NOC proceedings, the order of evidence was reversed

Pfizer v. Pharmascience, merits of NOC proceeding

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • January 20 2010

The Court granted prohibition to Pfizer and found that Pharmascience’s allegations of invalidity were not justified

Sanofi-Aventis v. ApotexNovopharmRiva, interlocutory motion to consolidate actions

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • January 20 2010

Sanofi brought a motion to consolidate three actions pertaining to damages pursuant to section 8 of the NOC Regulations

Eli Lilly Canada Inc. v. Apotex; application to declare NOA null and void

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 2 2009

Apotex sent a NOA regarding the validity of a patent list on the Patent Register for an orally disintegrating tablet form of a drug

Apotex v. Janssen

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • July 27 2009

The Court of Appeal overturned the decision of the applications judge in issuing a prohibition order and sent it back for reconsideration

Sanofi-Aventis v. Novopharm; preliminary questions regarding costs assessment

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 2 2009

Sanofi had brought a proceeding against Novopharm and joined Schering as the respondentpatentee pursuant to the NOC Regulations